Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
Challenges today concern chronic myeloid leukemia (CML) patients resistant to imatinib. There is growing evidence that imatinib-resistant leukemic cells present abnormal glucose metabolism but the impact on mitochondria has been neglected. Our work aimed to better understand and exploit the metaboli...
Guardado en:
Autores principales: | Jérome Kluza, Manel Jendoubi, Caroline Ballot, Abir Dammak, Aurélie Jonneaux, Thierry Idziorek, Sami Joha, Véronique Dauphin, Myriam Malet-Martino, Stéphane Balayssac, Patrice Maboudou, Gilbert Briand, Pierre Formstecher, Bruno Quesnel, Philippe Marchetti |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/30a12df69d4f470da9eece553ed01f44 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
por: Silvia Catellani, et al.
Publicado: (2011) -
Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics
por: Lars Velten, et al.
Publicado: (2021) -
GENERIC IMATINIB VS GLEEVEC
por: Katia Borgia Barbosa Pagnano
Publicado: (2021) -
Periorbital edema secondary to imatinib mesylate
por: Collin M McClelland, et al.
Publicado: (2010) -
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
por: Hyerin Park, et al.
Publicado: (2021)